PMID- 15958822
OWN - NLM
STAT- MEDLINE
DCOM- 20051206
LR  - 20151119
IS  - 0931-0509 (Print)
IS  - 0931-0509 (Linking)
VI  - 20 Suppl 6
DP  - 2005 Jun
TI  - Managing anaemia and diabetes: a future challenge for nephrologists.
PG  - vi21-5
AB  - The combination of diabetes and chronic kidney disease is associated with 
      increased mortality and reduced quality of life. Recent studies have shown that, 
      in general, late referral of patients to the renal unit increases mortality, and 
      that patients with diabetes who are referred late have a particularly poor 
      prognosis. Several co-morbid conditions have been shown to contribute to poor 
      patient outcomes, including both cardiovascular disease and anaemia. In patients 
      with diabetic nephropathy, anaemia is more severe and is seen earlier than in 
      patients with non-diabetic renal disease. Although the treatment of anaemia with 
      recombinant human erythropoietin (rhEPO; epoetin) is well established, the only 
      data currently available concerning the effects of early intervention in patients 
      with diabetic nephropathy are from small-scale studies. Therefore, two 
      large-scale studies have been designed to provide information on the efficacy of 
      epoetin treatment and on how current management strategies might be improved. The 
      Anaemia CORrection in Diabetes (ACORD) study will provide information on the 
      potential cardiac benefits of early anaemia management in patients with early, 
      type 2 diabetic nephropathy. The Individualised Risk-profiling In DIabEtes 
      Mellitus (IRIDIEM) study will provide evidence-based guidance in risk factor 
      management, by assessing the efficacy of individualized interventions.
FAU - Ritz, Eberhard
AU  - Ritz E
AD  - University of Heidelberg, Heidelberg, Germany. Prof.E.Ritz@t-online.de
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Nephrol Dial Transplant
JT  - Nephrology, dialysis, transplantation : official publication of the European 
      Dialysis and Transplant Association - European Renal Association
JID - 8706402
RN  - 0 (Hematinics)
RN  - 0 (Recombinant Proteins)
RN  - 0 (epoetin beta)
RN  - 11096-26-7 (Erythropoietin)
RN  - 64FS3BFH5W (Epoetin Alfa)
SB  - IM
MH  - Anemia/*etiology/*therapy
MH  - Cardiovascular Diseases/etiology/prevention & control
MH  - Diabetes Mellitus, Type 2/*complications/*therapy
MH  - Diabetic Nephropathies/*etiology/mortality/therapy
MH  - Epoetin Alfa
MH  - Erythropoietin/therapeutic use
MH  - Hematinics/therapeutic use
MH  - Humans
MH  - Kidney Failure, Chronic/*etiology/mortality/therapy
MH  - Recombinant Proteins
MH  - Referral and Consultation
MH  - Survival Rate
RF  - 32
EDAT- 2005/06/17 09:00
MHDA- 2005/12/13 09:00
CRDT- 2005/06/17 09:00
PHST- 2005/06/17 09:00 [pubmed]
PHST- 2005/12/13 09:00 [medline]
PHST- 2005/06/17 09:00 [entrez]
AID - 20/suppl_6/vi21 [pii]
AID - 10.1093/ndt/gfh1093 [doi]
PST - ppublish
SO  - Nephrol Dial Transplant. 2005 Jun;20 Suppl 6:vi21-5. doi: 10.1093/ndt/gfh1093.